TrialJournal of hematology & oncology2020

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.

Laurie H Sehn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.